The Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional) from the National Institutes of Health (NIH) supports applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism. Applications are open to researchers at research institutions in the USA and worldwide, including small businesses and other for-profit organizations.
The grant provides funding for up to 5 years (plus indirect costs).
Funding opportunity number: PAR-25-039
Applications are due on June 5, 2026.